title: Co-activation of AMPK and mTORC1 as a new therapeutic option for acute myeloid leukemia.
abstract: We report the therapeutic potential of GSK621, an AMP-activated protein kinase (AMPK) agonist, in acute myeloid leukemia (AML). GSK621-induced cytotoxicity is restricted to AML cells compared to normal hematopoietic progenitors due to a unique synthetic lethal interaction of co-activation of AMPK and mammalian target of rapamycin complex 1 (mTORC1) that involves the stress response pathway. AMPK activation thus represents an attractive perspective for cancer therapy.
authors.affiliation: INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France.
authors.forename: Pierre
authors.initials: P
authors.lastname: Sujobert
authors.affiliation: INSERM U1016, Institut Cochin, CNRS UMR8104, Paris, France; Université Paris Descartes, Faculté de Médecine Sorbonne Paris Cité, Paris, France; Equipe Labellisée Ligue Nationale Contre le Cancer (LNCC), Paris, France.
authors.forename: Jerome
authors.initials: J
authors.lastname: Tamburini
keywords: AML; AMPK; GSK621; mTORC1; synthetic lethality